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Antibodies  to neuraminidase  (NA),  the  second  most  abundant  surface  protein  on  inﬂuenza  virus,  con-
tribute  toward  protection  against  inﬂuenza.  The  traditional  thiobarbituric  acid (TBA)  method  to  quantify
NA  inhibiting  antibodies  is  cumbersome  and  not  suitable  for routine  serology.  An  enzyme-linked  lectin
assay  (ELLA)  described  by Lambre  et  al. (1990)  is a practical  alternative  method  for  measuring  NA  inhi-
bition  (NI) titers.  This  report  describes  optimization  of the ELLA  for measuring  NI titers  in human  seraeywords:
nﬂuenza
euraminidase
nzyme-linked lectin assay
erology
ntibody
against  inﬂuenza  A  viruses,  using  H6N1  and  H6N2  viruses  as  antigens.  The  optimized  ELLA  is subtype-
speciﬁc  and  reproducible.  While  the titers  measured  by  ELLA  are  somewhat  greater  than  those  measured
by  a  miniaturized  TBA  method,  seroconversion  rates  are  the  same,  suggesting  similarity  in  assay  sensi-
tivity  under  these  optimized  conditions.  The  ELLA  described  in  this  report  provides  a practical  format  for
routine  evaluation  of human  antibody  responses  to  NA.
Published  by Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY-NC-ND  license. Introduction
Neuraminidase (NA) inhibiting antibodies are associated with
rotection against inﬂuenza (Murphy et al., 1972) and correlate
ith reduced viral shedding and disease symptoms in a human
hallenge study (Clements et al., 1986). These antibodies contribute
o immunity by inhibiting release and spread of newly formed
irus particles from infected cells (Compans et al., 1969). Despite
he established importance of NA inhibiting (NI) antibodies, these
iters are rarely measured in seroepidemiologic or vaccine stud-
es because the traditional thiobarbituric acid (TBA) assay used
o quantify these antibodies is impractical for large numbers of
amples and employs hazardous chemicals. Alternative assays that
ave been developed include a miniaturization of the TBA method
Sandbulte et al., 2009) and an enzyme-linked lectin assay (ELLA)
Abbreviations: ELLA, enzyme-linked lectin assay; HA, hemagglutinin; HI,
A inhibition; NA, neuraminidase; NI, NA inhibiting/inhibition; PBS, phosphate-
uffered saline; PNA, peanut agglutinin; TBA, thiobarbituric acid.
∗ Corresponding author at: 10903 New Hampshire Avenue, Building 72, Room
328, HFM445, Silver Spring, MD  20993, USA. Tel.: +1 240 402 9505.
E-mail addresses: Laura.Couzens@fda.hhs.gov (L. Couzens), Jin.Gao@fda.hhs.gov
J. Gao), k.westgeest@erasmusmc.nl (K. Westgeest), sandbult@iastate.edu (M.  Sand-
ulte), Vladimir.Lugovtsev@fda.hhs.gov (V. Lugovtsev), r.fouchier@erasmusmc.nl
R. Fouchier), Maryna.Eichelberger@fda.hhs.gov (M. Eichelberger).
ttp://dx.doi.org/10.1016/j.jviromet.2014.09.003
166-0934/Published by Elsevier B.V. This is an open access article under the CC BY-NC-N(http://creativecommons.org/licenses/by-nc-nd/3.0/).
(Lambre et al., 1990). The read-out of each method is different –
while both quantify products of enzyme activity, the TBA method
measures the amount of free sialic acid, the soluble product of NA
activity, whereas ELLA measures the amount of penultimate galac-
tose that becomes available after the terminal sialic acid is cleaved
from substrate. Despite this difference, the assay principals are the
same, usually employing whole virus as a source of antigen and
using fetuin, a highly glycosylated protein, as substrate.
Since HA-speciﬁc antibodies in human sera can block access of
substrate to NA, it is essential to use viruses with a HA subtype
that is not in circulation when performing either of these assays
for human serology. The assay described in this manuscript uses
reverse genetics-derived H6 reassortant viruses that contain the
targeted NA (Sandbulte et al., 2011). This strategy follows the orig-
inal approach to measure NA inhibition antibody titers in which H6
reassortant viruses generated by classical reassortment were used
in the traditional TBA method (Kilbourne et al., 1968, 1990).
The substrate for NA, fetuin, is coated onto the surface of 96
well plates used in the ELLA. Virus is incubated in the wells in the
presence or absence of serial serum dilutions. NA cleaves termi-
nal sialic acid moieties from glycoprotein complexes, and therefore
enzyme activity can be quantiﬁed by measuring the amount of
galactose that is consequently at the terminus of each carbohy-
drate complex. This is accomplished using peroxidase-conjugated
peanut-agglutinin (PNA), a lectin with speciﬁcity for terminal
D license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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alactose. Following incubation with PNA-peroxidase, a substrate
or peroxidase is added, leading to a colorimetric change propor-
ional to NA activity. The ELLA has recently been used to measure
I antibody titers in a number of studies (Cate et al., 2010; Couch
t al., 2012, 2013; Fritz et al., 2012; Fries et al., 2013), but assay
ptimization and details of the assay procedure to measure titers
gainst the NA of human seasonal viruses have not been reported.
his report describes steps that are important for obtaining consis-
ent results and provide data to support the use of ELLA in human
erology.
. Materials and methods
.1. Viruses
Reassortant inﬂuenza viruses were generated by reverse genet-
cs as described previously (Hoffmann et al., 2000; Sandbulte
t al., 2011). These viruses contain the HA (H6) gene from
/turkey/Massachusetts/3740/1965, gene segments encoding
nternal proteins from A/Puerto Rico/8/1934 (PR/34), and one of
he following NA gene segments: N1 of A/Texas/36/1991 (TX/91),
/New Caledonia/20/1999 (NC/99), A/Solomon Islands/3/2006
SI/06), A/Brisbane/59/2007 (BR/07), A/California/07/2009 (CA/09);
nd N2 of A/Wisconsin/67/2005 (WI/05) or A/Uruguay/716/2007
UR/07). The following wild type inﬂuenza B viruses were used:
/Florida/4/2006 (B/FL/06) as representative of the B/Yamagata
ineage and B/Brisbane/60/2008 (B/BR/08) as representative of the
/Victoria lineage. Viruses were cultured in the allantoic cavity of
–12 day old embryonated chicken eggs at 33 ◦C, harvested 72 h
ost-inoculation and stored in aliquots at −80 ◦C.
.2. Serum samples
The following animal sera were used: ferret antisera against
C/99, UR/07, B/FL/06 and B/BR/08 generated by infecting ferrets
ith the respective wild-type inﬂuenza viruses, and cotton rat sera
rom naïve as well as PR/34 (H1N1)-immune animals. Ferret and
otton rat inoculations were performed following federal guide-
ines under a protocol approved by the institutional Animal Care
nd Use Committee. Pooled rabbit antisera (Capralogics, Hardwick,
A,  USA) collected before and after immunization with puriﬁed NA
ere also used in this study. The NA was puriﬁed from WI/05 by cel-
ulose acetate electrophoresis (Sultana et al., 2011). De-identiﬁed
uman sera were obtained from a clinical vaccine study in which
roups of young, healthy adults were immunized with either a live
r inactivated trivalent seasonal inﬂuenza vaccine. The study was
pproved by the Institutional Research Involving Human Subjects
ommittee. Antibody and cellular immune responses were mea-
ured before and 4 weeks after vaccination; these results were
eported previously (Eichelberger et al., 2011). Unless otherwise
oted, antisera were heat-inactivated at 56 ◦C for 45 min  before
onducting assays.
.3. ELLA procedure
The principles of the ELLA described by Lambre et al. (1990)
nd Cate et al. (2010) were followed to optimize and validate the
ethod. The standard operating procedure (SOP) for this method is
ncluded in this manuscript as supplementary information. Fetuin
Sigma, St. Louis, MO,  USA) was diluted to 25 g/ml in 0.1 M phos-
hate buffered saline (PBS) and 100 l added to each well to coat
igh-binding 96-well plates (Nalge Nunc, Rochester, NY, USA).
lates were stored at 4 ◦C and used 24 h to 2 months after coating.
o determine the amount of antigen (virus) to use in ELLA, serial
ilutions of the targeted H6 reassortant virus were prepared in Dul-
ecco’s PBS (pH 7.4)–0.9 mM CaCl2–0.5 mM MgCl2 containing 1%cal Methods 210 (2014) 7–14
bovine serum albumin (BSA) and 0.5% Tween and then dispensed
(50 l/well) into fetuin-coated plates containing an equal volume
of PBS. The plates were incubated for 16–18 h at 37 ◦C, then washed
6 times with PBS–0.05% Tween 20 (PBST) before adding 100 l
peanut agglutinin (PNA) conjugated to horse-radish peroxidase
(HRPO, Sigma). PNA–HRPO was  used at the highest dilution that
gave the maximum signal when titrated on fully digested fetuin.
Plates were incubated at room temperature for 2 h and washed 3
times with PBST before adding o-phenylenediamine dihydrochlo-
ride (OPD, Sigma) to the plate. The color reaction was  stopped
after 10 min  by the addition of 1 N H2SO4. The plates were read at
490 nm for 0.1 s using a Victor V 96-well plate reader (PerkinElmer,
Waltham, MA,  USA). The dilution of virus (antigen) that resulted in
90–95% maximum signal was  elected for use in serology.
To measure the NI titers, each serum sample was heat treated
(56 ◦C for 45 min) and then diluted serially in PBS–BSA. Fifty
microliters of each dilution was added to duplicate wells of a fetuin-
coated plate. An equal volume (50 l) of the selected virus dilution
was added to all serum-containing wells in addition to at least 4
wells containing diluent without serum that served as a positive
(virus only) control. At least 4 wells were retained as a background
control (PBS only). The plates were incubated for 16–18 h at 37 ◦C.
As described for the virus titration, the plates were washed and
PNA–HRPO was  added to all wells. After a 2 h incubation period, the
plates were washed and peroxidase substrate (OPD) was added. The
color reaction was stopped after 10 min  and absorbance read. The
mean absorbance of the background (Abkg) was subtracted from the
test wells and positive control (Apos) wells. The percent NA activity
was calculated by dividing the mean absorbance of duplicate test
wells (Atest) by the mean absorbance of virus only wells and mul-
tiplied by 100, i.e. (Atest − Abkg)/(Apos − Abkg) × 100. To determine
percent NA inhibition, the percent activity was subtracted from
100. The NI titers were deﬁned as the reciprocal of the last dilu-
tion that resulted in at least 50% inhibition. An alternative way to
report results is to calculate the titers of replicate wells indepen-
dently and then report the geometric mean of the duplicates as the
50% end-point NI titer. In some instances the exact 50% inhibition
(IC50) was  determined by 4 parameter logistics regression analysis
(GraphPad Prism software). An assay was  considered valid if the
background absorbance was less than 10% of the virus only con-
trol, control sera had a similar NI titer to the median established in
previous assays (≤2-fold difference), and the raw A490 values of the
duplicates did not vary more than 20%.
2.4. Miniaturized TBA method
The miniaturized TBA method was  followed as described previ-
ously (Sandbulte et al., 2009).
2.5. Statistical analysis
Microsoft Ofﬁce Excel was  used to calculate standard deviations
(SDs) of NI titers, percent coefﬁcient of variation (%CV) for repeat
assays and Pearson’s correlation coefﬁcient. Bland–Altman analysis
(Bland and Altman, 1999) was performed using GraphPad Prism to
assess the agreement between ELLA and TBA results.
3. Results
3.1. Assay optimization
The published ELLA method (Lambre et al., 1990) was  optimized
for routine analysis of human sera. This assay uses reassortant
viruses with a mismatched HA as antigen (source of NA enzyme)
to avoid non-speciﬁc inhibition by H1 and H3-speciﬁc antibodies
in human sera. The H6 reassortant viruses containing the targeted
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Fig. 1. Examples of H6N1 and H6N2 virus titrations. Serial dilutions of H6N1NC/99 (N1 shown in red ﬁlled symbols) and H6N2WI/05 (N2 shown in black open symbols) were
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then added as substrate to all wells. OPD was used because it is
used for other assays in our laboratory, however, it can be replaced
by 3,3′,5,5′-tetramethylbenzidine (TMB).
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Serum diluonncubated for 18 h in fetuin-coated plates and the reactivity with PNA determined a
f  N1 and N2 antigens. The enzyme activity of each antigen stock was determined p
A were generated by reverse genetics as described previously
Hoffmann et al., 2000; Sandbulte et al., 2009). Fetuin was used
s substrate in the assay.
The assay requires the use of a deﬁned amount of antigen
enzyme). Titration of different batches of H6N1 and H6N2 viruses
n fetuin-coated plates resulted in expected sigmoidal regression
urves, with maximum signal at A490 nm ∼3.0 and background <0.2.
acterial NA puriﬁed from Vibrio cholera (Sigma) resulted in a
imilar titration curve. The linear range of absorbance values corre-
ponded to enzyme activity units of 1–15 U NA/ml (Fig. 1). Three
ifferent human sera and normal rabbit serum were titrated at
ach virus concentration, showing dependence of NI titer on the
mount of antigen, with low titers at high virus concentrations and
igh titers when low amounts of antigen were added to the wells
Table 1). A minimal difference in NI titer was recorded when dilu-
ions of virus that resulted in 50–90% of the maximum signal were
sed. This corresponded to the amount of virus within the linear
egion of the virus titration curve and resulted in a signal 5–10
imes greater than background. Under optimized conditions this
orresponded to absorbance signals (A490nm) of 1.5–2.5. To exploit
he full range of the assay, the dilution of virus that was at the
op of the linear range (90–95% of maximal signal) was  elected for
outine serology because this amount of virus resulted in great-
st signal:noise ratio and allowed maximum assay range (16-fold
ncreases in titer could be measured). In the examples shown in
able 1, the amounts of virus selected for serology were dilutions
f 1:640 for CA/09 and 1:60 for UR/07.
Since human sera usually contain NA-speciﬁc antibodies, initial
xperiments used sera from naïve animals to establish conditions
hat minimize the effect of non-speciﬁc inhibitors. Naive cotton rat
erum tested in ELLA against different dilutions of PR/34 showed
onsiderable inhibition of NA activity when the recommended
mount of virus was used (Fig. 2). Freeze-thawing (F/T) of the serum
ample did not reduce the non-speciﬁc inhibition signiﬁcantly.
owever, heat-treatment at 56 ◦C for 45–60 min  was  sufﬁcient to
educe non-speciﬁc inhibition so that titers of naïve serum against
ither H6N1 or H6N2 reassortant viruses were <5. Non-speciﬁc
nhibition of NA activity is dependent on HA subtype and there-
ore needs to be considered when assays use antigens that contain
A subtypes other than H6. In instances when heat-inactivation is
nsufﬁcient to eliminate inhibitors, serum samples can be treated
ith receptor destroying enzyme (RDE) prior to heat treatment
results not shown).ribed in Section 2. Average absorbance of 2 wells is plotted against enzyme activity
usly using bacterial neuraminidase as the standard.
Following heat-treatment, 2-fold dilutions of serum samples
were added to duplicate wells of a washed, fetuin-coated plate. An
equal volume of virus (antigen) was then added. Initial experiments
included an incubation step of serum and virus in a ‘dilution’ plate.
This resulted in inconsistent results, most likely reﬂecting adher-
ence of virus to the dilution plate wells. The assay was therefore
simpliﬁed to add serum dilutions and virus directly to the fetuin-
coated plate.
Our initial experiments hoped to reduce assay time by opti-
mizing conditions to allow short virus and substrate incubation
times. However, the overall signal obtained after short incubations
was low (data not shown) and therefore to preserve assay robust-
ness, the assay was optimized for overnight (16–18 h) incubation
of virus/serum on the fetuin-coated plate. After this incubation, the
lowest dilution of PNA-HRPO that resulted in maximum signal was
added and the plates held at room temperature for 2 h. OPD wasFig. 2. Heat treatment of sera is required to reduce non-speciﬁc inhibition of NA
activity. Serum from naïve cotton rats was either not treated, heated at 56 ◦C
for  60 min, frozen and thawed 3 times (F/T), or heat-treated in addition to 3
freeze–thaws.
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Table  1
NA inhibition titers of serum samples incubated with different amounts of antigen.
Serum sample Dilution of H6N1CA/09 (percent of maximum signal)
160 (100) 320 (98) 640 (89) 1280 (80) 2560 (46) 5120 (30) 10,240 (18) 20,480 (11)
1 <10 <10 <10 <10 <10 <10 10 10
2  40 40 80 160 160 160 320 320
3  320 640 1280 2560 2560 5120 5120 5120
4  160 320 640 640 1280 2560 5120 5120
Dilution of H6N1UR/07 (percent of maximum signal)
20 (100) 40 (99) 80 (82) 160 (67) 320 (43) 640 (23) 1280 (15) 2560 (8)
1 10 <10 <10 <10 10 10 20 20
80 80 160 160
640 640 2560 2560
320 320 640 640
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Fig. 3. Titration of sera against H6N1NC/99 (solid lines) and H6N2WI/05 (dashed lines)
viruses. Percent enzyme inhibition for serial dilutions of serum 1 (ﬁlled circle) and
serum 2 (ﬁlled diamond) is shown on each graph with the dashed horizontal line
indicating 50% inhibition. The NA inhibition titers of sera 1 and 2 against the NA of
T
S
m2  20 40 40 80 
3  80 160 320 320 
4  40 80 80 160 
.2. Assay speciﬁcity
The speciﬁcity of ELLA was examined with monospeciﬁc sera.
hese included antisera from ferrets previously infected with NC/99
H1N1), UR/07 (H3N2), B/FL/06 and B/BR/08 and antiserum from
abbits immunized with NA puriﬁed from WI/05 (H3N2). NI titers
ere measured against H6N1NC/99, H6N2WI/05, and H6N2UR/07,
/FL/06 and B/BR/08. Ferret anti-NC/99 inhibited enzyme activity
f H6N1NC/99 by a 64-fold higher titer than H6N2 viruses (Table 2).
imilarly, rabbit antiserum speciﬁc for WI/05, had a 32-fold higher
nhibition titer against H6N2WI/05 than H6N1NC/99. Control sera did
ot inhibit enzyme activity of H6N1NC/99 or H6N2WI/05. Ferret anti-
/FL/06 (B/Yamagata lineage) and anti-B/BR/08 (B/Victoria lineage)
ntisera did not react with the NA of inﬂuenza A viruses demon-
trating speciﬁcity for the B antigens. Since H6 reassortants cannot
e generated with the NA of B strains, the antibody titers mea-
ured against B viruses may  not accurately quantify NA-speciﬁc
ntibodies because HA-speciﬁc antibodies may  hinder access of
ubstrate to NA’s active site and thereby contribute to the reduced
ignal; nevertheless, the NI titer of the B/FL/06-speciﬁc serum
as greater against the homologous virus than the heterologous
/Victoria-lineage and vice versa, suggesting that these NAs are
ndeed antigenically distinct. Overall, these results demonstrate
hat virus-speciﬁc antisera show speciﬁcity for the homologous NA,
lthough a small degree of cross-reactivity with a different subtype
s observed when sera have very high homologous NI titers.
.3. Assay linearity
NA inhibition titration curves were established for human
erum samples having a range of titers against N1NC/99 and N2WI/05.
his was accomplished by adding serial dilutions of serum samples
o a fetuin-coated plate in duplicate wells, followed by addition
f standardized amounts of H6N1NC/99 and H6N2WI/05 antigens.
fter incubation overnight, the assay was completed as outlined
able 2
peciﬁcity of ELLA.
NA antigena NI titer of antiserum against
None H1N1 H3N2
NC/99 WI/05
NC/99 (N1) <10 1280 80 
WI/05 (N2) <10 10 2560 
UR/07 (N2) 10 20 2560 
B/FL/06 <10 <10 40 
B/BR/08 <10 <10 <10 
a The N1 and N2 antigens were in the form of H6N1 and H6N2 reassortant viruses, resp
b Antisera against NC/99, UR/07, B/FL/06 and B/BR/08 were generated by infection of fe
ixed  with an equal volume of Freund’s complete adjuvant. The puriﬁcation and mixing NC/99 were 320 and 20 respectively; the NA inhibition titers of sera 1 and 2 against
the NA of WI/05 were 20 and 40 respectively.
in the materials and methods section (the detailed method is pro-
vided as supplementary information). Absorbance increased as the
amount of serum decreased, indicating the presence of increas-
ing amounts of active NA. Percent inhibition was proportional to
the amount of serum and followed a sigmoidal curve. Examples of
human serum titrations are shown in Fig. 3; one serum has a rela-
tively high titer against the N1 antigen but lower titer against the
N2 antigen whereas the second serum has similar titers against N1
and N2 antigens. To assess the linearity of the assay, NI antibody
 B
b UR/07 B/FL/06 B/BR/08
<10 <10 <10
80 <10 <10
160 <10 <10
<10 640 40
<10 40 160
ectively. Wild type B viruses were used in this assay.
rrets. The anti-WI/05 serum was from rabbits immunized with puriﬁed NA puriﬁed
may  have resulted in denaturation of some of the antigen.
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Table  3
Assay precision: titration of samples within the same and different plates. Four replicates of each titration were conducted on each plate.
Plate Sample 1 Sample 2 Sample 3 Sample 4 Sample 5
Titer ± SDa %CV Titer ± SD %CV Titer ± SD %CV Titer ± SD %CV Titer ± SD %CV
Antigen 1: H6N1NC/99
1 <2.3 0 5.3 ± 0 0 6.3 ± 0 0 7.3 ± 0 0 6.3 ± 0 0
2  <2.3 0 6.1 ± 0.5 8.2 6.3 ± 0 0 7.3 ± 0 0 6.3 ± 0 0
3  <2.3 0 5.6 ± 0.5 8.9 6.3 ± 0 0 7.3 ± 0 0 6.3 ± 0 0
All  <2.3 0 5.6 ± 0.5 8.7 6.3 ± 0 0 7.3 ± 0 0 6.3 ± 0 0
Antigen 2: H6N2WI/05
1 <2.3 0 12.3 ± 0 0 4.3 ± 0 0 4.3 ± 0 0 5.7 ± 0.5 8.9
2  <2.3 0 12.3 ± 0 0 4.3 ± 0 0 4.3 ± 0 0 5.3 ± 0 0
3  <2.3 0 12.3 ± 0 0 4.3 ± 0 0 4.3 ± 0 0 6.3 ± 0 0
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a The titer is shown as log 2.
iters of different dilutions of 4 different samples with known titers
ere measured. The results demonstrated that the IC50 calculated
or each dilution varied <10% from the assigned value (results not
hown) and supported relative accuracy of the method for measur-
ng NI antibody titers over a range of 5–2560.
.4. Assay precision
Repeatability of the assay was determined by measuring geo-
etric mean NA inhibition titers (GMT) of 5 sera. One operator
erformed the assays in which each sample was tested 8 times on
 separate 96-well plates. The results obtained for titrations within
he same plate were highly reproducible (CV <10%). Plate-to-plate
ariability was also minimal (Table 3). In some instances (e.g. sam-
le 2 tested against H6N1 virus), the percent inhibition calculated
or a particular dilution was close to 50% inhibition in all tests but
ecause the titer is deﬁned as the reciprocal of the last dilution
hat resulted in at least 50% inhibition, a lower titer was assigned
ven when percent inhibition was 49%. As a result there were some
nstances when a 2-fold difference was reported for replicate serum
itrations even though the assay variability was minimal (the aver-
ge relative standard deviation calculated at approximately 50%
ercent inhibition for assays against either N1 or N2 antigens was
%). This was the largest difference observed for sample 2 shown in
able 3 (H6N1NC/99 antigen), even when assays were run on differ-
nt days (total of 24 titrations). The titers for other samples shown
n Table 3 were the same in all 24 tests, reﬂecting the unambigu-
us assignment of titer when percent inhibition was well below
0% (e.g. sample 1 against either the N1 or N2 antigen) and when
he percent inhibition was clearly greater than 50% at the assigned
iter (e.g. sample 2 against the N2 antigen). Therefore, these results
how that when all samples are considered for repeatability, a
-fold difference in 50% end point titer is statistically signiﬁcant
p ≤ 0.05). It is likely that smaller differences in titers reported as
C50 or geometric means from repeat assays would be considered
igniﬁcant.
Intermediate precision of the assay was also assessed, with
 technicians running the same samples. Both operators were
xperienced and trained in the same standard operating pro-
edure. Comparable results were obtained for each sample,
ith measurement of no more than a 2-fold difference in
iter.
Changes to the source of fetuin, storage conditions of fetuin (4 ◦C
nstead of −20 ◦C), use of coated plates stored for different lengths
f time at 4 ◦C and use of different plate readers were evaluated for
ssay robustness. The changes were acceptable because the mod-
ﬁcations did not result in NI titers that differed from the titers
btained with the written SOP by more than 2-fold. As described
arlier, the amount of antigen (virus) in the assay was  critical and
herefore the dilution of virus used for the purpose of serology was0 0 4.3 ± 0 0 5.7 ± 0.5 8.7
deﬁned as the dilution that results in 90–95% of maximum signal
(Table 1). Although assay sensitivity may  be increased by using less
antigen (allowing elucidation of smaller differences in antigenic
structure), an amount of antigen that gives a signal ≥10-fold back-
ground and within the linear range of the virus titration resulted in
reproducible sample titers.
3.5. Comparability between ELLA and mini-TBA methods
Comparison of NI antibody titers of ferret antisera measured
by the mini-TBA and ELLA against a number of N1 (NA of TX/91,
NC/99, SI/06 and BR/07) and N2 (NA of AI/68, WU/95, SY/97, PA/99,
WY/03, NY/04, UR/07) antigens demonstrated excellent correla-
tion between NI titers, although the absolute titer was somewhat
greater when measured by ELLA (Fig. 4A and B; Fig. S1A, B). This
study also compared absolute titers and response rates measured
by mini-TBA and ELLA methods of 32 serum pairs reported previ-
ously for a clinical study comparing responses to live, attenuated
and inactivated split trivalent inﬂuenza vaccines (Hassantouﬁghi
et al., 2010). As for the ferret sera and reported by Fritz et al. (2012),
the human antibody titers measured by mini-TBA and ELLA meth-
ods showed some correlation (Fig. 4C and D), however NI titers
generated by ELLA were often greater than the titers measured by
the mini-TBA method (Fig. S1C, D). Bland–Altman analysis showed
better agreement of ELLA and mini-TBA NI antibody titers for ferret
sera than human sera (Fig. S1), with the mini-TBA assay generat-
ing lower NI antibody titers against both H6N1 and H6N2 antigens
for the majority of human sera tested. The bias (±SD) for agree-
ment between TBA and ELLA titers against the H6N1 antigen was
−2.2 (±15.7) for ferret sera but −45.0 (±19.3) for human sera; and
against the H6N2 antigen was  −2.8 (±30.2) for ferret sera but −22.1
(±24.2) for human sera.
There was  similar sensitivity in determining seroconversion by
ELLA and mini-TBA methods. For paired samples taken before vac-
cination and 4 weeks later, increases in NI titers were evident
in a similar proportion of volunteers; of 32 volunteers, the mini-
TBA method identiﬁed 12 volunteers with increased serum NA
inhibition titers against the N1 component (NC/99) and 13 volun-
teers with increased NA inhibition titers against the N2 component
(WI/05) after vaccination (Hassantouﬁghi et al., 2010). The ELLA
identiﬁed a similar number of volunteers that had increased NI
titers following vaccination: the 12 volunteers identiﬁed by mini-
TBA as well as two  additional subjects had increased NI titers
against the N1 component (14 seroconversions when consider-
ing a 2-fold increase as signiﬁcant); 12 of the 13 volunteers who
had increased NI titers identiﬁed by mini-TBA against the N2 com-
ponent were identiﬁed by ELLA in addition to 2 volunteers who
did not have increased titers measured in the mini-TBA assay
(Table 4).
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Table  4
Assay sensitivity: NA inhibition titers against A/WI/05 (H3N2) following seasonal inﬂuenza vaccination of healthy adults.
Volunteer # Mini-TBA ELLA
Pre Post Fold increase Pre Post Fold increase
1 10 10 20 20
3  40 40 40 40
4  10 10 20 20
5  40 20 20 20
6  5 10 2 10 20 2
7  10 20 2 20 40 2
8  5 20 4 10 40 4
9  <5 <5 <10 <10
10  <5 5 2 <10 10 2
11  10 10 10 20 2
12  20 40 2 10 40 4
13  80 80 40 40
14  5 5 20 20
15  20 20 20 20
17  10 5 20 20
18  10 20 2 10 20 2
19  <5 5 2 <10 10 2
20  10 10 40 40
21  20 20 40 80 2
22  10 10 20 20
23  10 10 40 20
24  10 10 40 40
25  10 10 20 20
26  40 40 40 40
28  10 20 2 20 40 2
29  10 20 2 20 40 2
30  10 40 4 20 80 4
31  10 10 40 40
32  20 40 2 40 80 2
33  10 20 2 20 40 2
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. Discussion
NA inhibiting antibodies correlate with reduction in inﬂuenza
isease (Murphy et al., 1972) and therefore serology that routinely
ncludes measurement of NI antibody titers is warranted. In the
ast, this was difﬁcult to accomplish with the standard TBA method,
ut development of a miniaturized TBA method (Sandbulte et al.,
009) and use of the enzyme-linked lectin assay (Lambre et al.,
990) have resulted in more practical platforms that have allowed
I titers to be measured in a number of studies. This report
escribes steps that are important for obtaining consistent results
nd demonstrates reproducibility of the ELLA method. An SOP that
an be used by investigators interested in performing this assay
outinely is provided as supplementary information.
This study is not the ﬁrst to use ELLA to measure human serum
I antibody titers – others have adapted the method published
y Lambre et al. (1990) and measured responses to NA in clini-
al studies that demonstrate a number of important points. Couch
t al. (2012) demonstrated that current inﬂuenza vaccines contain
mmunogenic amounts of NA and that NI antibody seroconversion
ates are greater when vaccine dose is increased (Cate et al., 2010).
ritz et al. (2012) compared the TBA and ELLA methods in a study
easuring NI titers after vaccination with a cell grown inactivated
hole virus H5N1 vaccine, demonstrating increased sensitivity of
LLA compared to the TBA method and showing excellent increases
n NI titer following a single dose of vaccine. NI titers were not
ncreased following a boost with this vaccine, possibly reﬂecting
ompetition between HA and NA antigens when they are presented
n the same whole virus (Johansson and Kilbourne, 1993). Since
ntigenic competition can be circumvented by immunizing with
issociated HA and NA antigens in mice (Johansson and Kilbourne,
996), it would be of interest to determine whether NI titers
re boosted following vaccination with split, inactivated inﬂuenza80 80
40 20
vaccines. NI titers measured after vaccination with VLPs suggest
the requirement for dissociated HA and NA antigens may not be
applicable to all vaccine types – responses to both HA and NA were
boosted following receipt of a second dose of adjuvanted H7N9 VLPs
(Fries et al., 2013). Interestingly, signiﬁcant increases in NI but not
HAI titers were evident after the ﬁrst dose of both unadjuvanted
and adjuvanted VLPs in this clinical study, suggesting that the N9
component of the VLP vaccine is more immunogenic than H7 or
that the NI assay has greater sensitivity than the HAI assay.
Although NI titers measured by ELLA correlate with the titers
measured in the mini-TBA assay, the values measured by ELLA are
often higher than measured by the more traditional assay. This dif-
ference was  more noticeable for titration of human sera than ferret
sera. It is not known whether the difference in assay bias reﬂects
the relatively low NI antibody titers of samples used in the human
analysis or whether it is due to qualitative differences in antibod-
ies or the presence of additional non-speciﬁc inhibitors in human
sera. Further studies to identify the factors that contribute to this
difference will be helpful in understanding how best to interpret
results and may  lead to assay improvements.
As for other serologic assays, non-speciﬁc inhibitors present in
serum samples need to be removed to avoid inaccurate measure-
ment of antibody titers. The non-speciﬁc inhibition observed in
the ELLA when animal (mouse and cotton rat) sera were tested
against H6N1 and H6N2 viruses was  removed by heat-treatment
(56 ◦C for 45 min), indicating the presence of thermolabile -
inhibitors. -inhibitors are Ca2+-dependent (C-type) lectins that
bind to mannose-rich glycans on glycoproteins (Anders et al.,
1990). Surfactant protein D is an example of a -inhibitor in the
lung; both infectivity and NA activity are inhibited in the pres-
ence of this inhibitor (White et al., 2005), indicating that SP-D has
capacity to bind to glycans on HA and NA, blocking their func-
tional activity. Conglutinin is a -inhibitor present in human serum
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Hartshorn et al., 1993) that may  contribute to non-speciﬁc inhibi-
ion of NA activity in the ELLA. Other non-speciﬁc inhibitors ( and
-class) of inﬂuenza HA have been described, particularly in rela-
ion to H3N2 virus hemagglutination and infectivity (Rogers et al.,
983; Matrosovich et al., 1998; Job et al., 2013), however, these
o not appear to result in non-speciﬁc inhibition of NA activity in
ssays that use H6 reassortant viruses as antigen.
Various forms of NA have been used in ELLAs – puriﬁed recom-
inant NA (Fritz et al., 2012), reassortant H6N1 and H6N2 viruses
this report), detergent split wild-type virus (Cate et al., 2010) and
irus like particles (Couch et al., 2013; Fries et al., 2013). Although
t is advantageous to use reassortant whole viruses that contain NA
n the “natural” form in ELLA, it has not been possible to gener-
te reassortant viruses expressing the NA of inﬂuenza B viruses
nd mismatched HAs. Puriﬁed recombinant NA protein or VLPs
re therefore needed to measure antibody responses to the NA of
nﬂuenza B viruses. Regardless of antigen source, all assays show a
orrelation between TBA and ELLA titers (our data as well as that
eported by Fritz et al. (2012)), with NI antibody titers measured
y ELLA somewhat greater than measured by the TBA method.
The results of assays that examine repeatability show that a
-fold rise in NA inhibition titer is indicative of seroconversion.et (A, B) and human (C, D) sera tested against H6N1 (A, C) and H6N2 (B, D) antigens.
each ﬁgure.
However, when consecutive serum samples are run on the same
plate and the raw data examined to verify that differences in titer
are not ambiguous (as may  be the case when percent inhibition
is close to 50%), assay variability may  be less, allowing a 2-fold
increase in NI titer to be used as evidence of a NA-speciﬁc antibody
response. Seroconversion rates that are based on 2-fold differences
in NI titer should be veriﬁed by performing repeat assays.
In conclusion, the steps taken to optimize and validate the
ELLA for measuring NA inhibiting antibody titers in human sera
are described in this report. The data show that this very practi-
cal assay is subtype speciﬁc, and yields reproducible results. Since
routine measurement of NI antibody titers is now possible, the
immunogenicity of NA in inﬂuenza vaccines can be examined more
routinely and NI antibody titers that correlate with protection from
clinical disease can be identiﬁed.
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